Dexrazoxane is a cardioprotective iron chelation drug.
Dexrazoxane does not interfere with the antineoplastic activity of doxorubicin or other antitumor drugs. In some case, especially cyclophosphamide, there was a markedly synergistic antitumor effect when combined with this drug.
Recommended dose rate in dogs is 25 mg/kg (ratio of 10-20:1 dexrazoxane:doxorubicin) given intravenously.
It can be given as a preventative drug, but recommendations are to restrict its use to known extravasation accidents, and this drug should be given within 6 hours following extravasation.
- FitzPatrick WM et al (2010) Safety of concurrent administration of dexrazoxane and doxorubicin in the canine cancer patient. Vet Comp Oncol 8(4)':273-282
- Imondi AR (1998) Preclinical models of cardiac protection and testing for effects of dexrazoxane on doxorubicin antitumor effects. Semin Oncol 25(4):22-30
- Baldwin JR et al (1996) Dose-independent pharmacokinetics of the cardioprotective agent dexrazoxane in dogs. Biopharm Drug Dispos 17(6):541-550
- Venable RO et al (2012) Dexrazoxane treatment of doxorubicin extravasation injury in four dogs. J Am Vet Med Assoc 240(3):304-307